Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection

被引：0
|
作者：
Chen, Yiwen [1 ]
Shen, Yan [1 ]
Zhang, Min [1 ]
Wu, Jian [1 ]
Gao, Shunliang [1 ]
Que, Risheng [1 ]
Yu, Jun [1 ]
Tang, Xiaofeng [1 ]
Bai, Xueli [1 ]
Liang, Tingbo [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：571 / 571
页数：1
相关论文
共 50 条
  • [1] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis
    Li, Chenggang
    Shen, Hanchuan
    Zhang, Hangyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Shen, Jian
    Xu, Guohui
    Bai, Yannan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 601 - 601
  • [4] Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience
    Zhang, Shenyu
    Yang, Guibin
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Luo, Dayong
    Wang, Jizhou
    Liu, Lianxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [5] The efficacy and safety study of thymosin a1 combined with PD-1 antibodies as adjuvant therapy in patients with hepatocellular carcinoma with high-risk recurrence factors after radical resection
    Zhu RongHua
    Huang Zhiyong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Adjuvant donafenib for patients with hepatocellular carcinoma at high risk of recurrence following radical resection: A multi-center, retrospective study in China
    Zhang, ShenYu
    Yang, Guibing
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Wang, Jizhou
    Luo, Dayong
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence-Free Survival in Hepatocellular Carcinoma Patients With High-Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study
    Shen, Hanchuan
    Liu, Bing
    Zhang, Hangyu
    Liu, Yang
    Li, Chenggang
    MEDCOMM-ONCOLOGY, 2025, 4 (01):
  • [8] An observational study of donafenib as adjuvant therapy to prevent hepatocellular carcinoma recurrence after curative surgery
    Shang, Changzhen
    Zhong, Jinyi
    Luo, Xuan
    Zhang, Jianlong
    Li, Huilong
    Hua, Yonglin
    Tan, Wenliang
    Lei, Zhang
    Chen, Yajin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A phase II study of tislelizumab (TIS) plus sitravatinib as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgical resection
    Liu, L-X.
    Peng, T.
    Liu, C.
    Wang, J.
    Zhu, G.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1444 - S1444
  • [10] A retrospective study of the efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with high-risk recurrence factors after hepatocellular carcinoma surgery
    Zou, Qifei
    Yuan, Shengxian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345